X0306
4
2019-02-06
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001423838
Grigoriadis Dimitri E.
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
0
1
0
0
Chief Research Officer
Common Stock
2019-02-06
4
S
0
531
84.0331
D
120065
D
Stock Option
81.05
2019-02-07
4
A
0
50005
0.00
A
2029-02-07
Common Stock
50005
50005
D
Restricted Stock Unit
2019-02-07
4
A
0
9254
0.00
A
Common Stock
9254
9254
D
Sale of 531 shares of common stock issued upon vesting of 1,525 restricted stock units on February 6, 2019 to cover payroll and withholding taxes, with the balance of the shares (994) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $80.98 to $85.76. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 7, 2019 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter.
Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 7, 2020, February 7, 2021, February 7, 2022, and February 7, 2023.
/s/ Darin Lippoldt, Attorney-in-Fact
2019-02-08